India, Nov. 20 -- Shares of Belite Bio, Inc (BLTE) are falling 12 percent on Friday trading after the company announced that the U.S. FDA has extended its review period for the New Drug Application for tinlarebant by three months.

The company's shares are currently trading at $132.38 on the Nasdaq, up 12.38 percent. The stock opened at $129.15 and has climbed as high as $135.00 so far in today's session. Over the past year, it has traded in a range of $108.00 to $200.00.

For comments and feedback contact: editorial@rttnews.com

Published by HT Digital Content Services with permission from RTT News....